CVS Caremark

Eli Lilly

Pharma

Lilly blows out tirzepatide sales expectations, raises guidance

In the third quarter, sales of Lilly's obesity blockbuster Zepbound reached nearly $3.6 billion, growing a staggering 185% year over year.

Fraiser Kansteiner Oct 30, 2025 10:39am

CVS won't cover Gilead's twice-yearly PrEP drug Yeztugo—for now

Aug 21, 2025 3:02pm

Wegovy

Novo's Wegovy secures preferred obesity spot on CVS formulary

May 1, 2025 2:39pm

CVS Health store front

CVS to replace branded Humira with biosims on some formularies

Jan 4, 2024 11:38am

CivicaPetersburg

Civica Rx draws $50M from California to produce low-cost insulin

Mar 20, 2023 11:45am

BMS flag

CVS Health returns BMS, Pfizer's Eliquis to formulary

Jun 24, 2022 8:29am